Get started
Author

Daniel Muñoz

Observed name: Daniel Munoz
ORCID: 0000-0002-0991-2992
Observed ORCID: 0000-0002-0991-2992
OpenAlex ID: A5101978734
Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial
2020 · Guillaume Marquis-Gravel, Matthew T. Roe, et al. · JAMA Cardiology · 84
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors
2023 · Saket Girotra, Amanda Stebbins, et al. · Journal of the American Heart Association · 2
PDF
Supplemental Figure 1: from β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation
2023 · Georgios Kallifatidis, Daniel Munoz, et al.
Supplemental Figure 1: from β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation
2023 · Georgios Kallifatidis, Daniel Munoz, et al.
Data from β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation
2023 · Georgios Kallifatidis, Daniel Munoz, et al.
Sex Differences in Effectiveness and Safety of Aspirin in Secondary Prevention of Cardiovascular Outcomes in Patients: a Subgroup Analysis From the Adaptable Study
2022 · Catherine P. Benziger, Amanda Stebbins, et al. · Journal of the American College of Cardiology
PDF
Works count: 6
Citation count: 86
H-index: 2
I10-index: 1
Year
Topic
Type